natgillin/translations-raw huggingface dataset:
said key blade having at least one longitudinal code pattern (103) for engaging with said integral key sensing part of said locking tumblers and making the key sensing part follow said longitudinal code pattern, when the key blade of said associated key is being inserted into the key slot, characterized in that 
- < navedeni krak ključa ima barem jedan uzdužni kodni uzorak (103) za međudjelovanje sa navedenim integralnim dijelom za raspoznavanje ključa navedenih čepića za zaključavanje 1 za osiguravanje da dio za raspoznavanje ključa slijedi navedeni uzdužni kodni uzorak, kada se krak ključa navedenog pripadajućeg ključa umeće u utor za ključ, naznačen time da
The compound for use of claim 8, wherein the lymphoma is Hodgkin's lymphoma. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je limfom Hodgkinov limfom.
The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods. 
Farmaceutski prihvatljive soli prema ovom izumu može se sintetizirati iz osnovnog spoja koji sadrži bazični ili kiseli ostatak uobičajenim kemijskim postupcima.
The process according to claim 1, wherein R1 and R2 independently represent C1 to C3 alkyl groups. The process according to claim 4, wherein at least one alkyl group is methyl. 
Postupak prema zahtjevu 1 ili 2, naznačen time da R; i R, neovisno predstavljaju C1 do C3 alkil skupine, poželjno metil.
At that, an ultrasonic magnetostrictive radiator is made in the form of a hollow cylinder, whose inside diameter matches the OWT inside diameter. 
Pri tome je ultrazvučni magnetostriktivni radijator napravljen u obliku šupljeg cilindra čiji je unutarnji promjer jednak unutarnjem promjeru CNL-a.
The anti-sclerostin antibody for use in the method of claim 14, wherein anti-sclerostin antibody: 
Antisklerostinsko antitijelo za primjenu u načinu prema zahtjevu 14, naznačeno time, što antisklerostinsko antitijelo:
A method of producing a soluble VH domain or a VH fusion protein which binds specifically to an antigen comprising: 
Postupak dobivanja topive Vgq domene ili Vu fuzijskog proteina koji se specifično veže na antigen koji sadrži:
coupling compound (1) and compound (2) under amide bond-forming conditions and deprotecting the product to form compound (3): where P is an amino-protecting group; 
(a) sprezanje spoja (1) i spoja (2) u uvjetima za nastanak amidne voze te skidanje zaštite, čime se dobiva spoj (3): m").
A pharmaceutical composition comprising suitable pharmaceutical excipients and also comprising a human in vivo clinical effective amount of a recombinant human growth hormone (rhGH) PEGylated prodrug conjugate, wherein PEG is linked to rhGH via a self hydrolysable (autocleavage) transient linker; said prodrug conjugate is characterized in that: 
PATENTNI ZAHTJEVI 1. Farmaceutski sastav koji obuhvaća prikladna pomoćna sredstva i također sadrži za čovjeka klinički učinkovitu količinu in vivo rekombinantnog ljudskog hormona rasta (rhGH)-PEGilirani predlijek-konjugata, pri čemu je PEG povezan s rhGH preko samohidrolizirajućeg (samocijepajućeg) prijelaznog poveznog elementa; gdje je navedeni predlijek-konjugat naznačen time, da:
The recombinant anti-a4 antibody molecule, or a4-binding fragment thereof, for use according to claim 5, wherein the patient has multiple sclerosis, asthma, rheumatoid arthritis, diabetes, optic neuritis, or Crohn's disease. 
Rekombinantna molekula protutijela ili njezin fragment koji veže a4, za uporabu prema zahtjevu 3, naznačena time, da pacijent ima upalni poremećaj, multiplu sklerozu, astmu, reumatoidni artritis, dijabetes, optički neuritis, Crohnovu bolest, akutni poremećaj, ozljedu kralježnice ili traumatsku ozljedu mozga.
The pharmaceutical composition of any one of claims 1 to 5, wherein said anti-human IL13 antibody or antigen binging fragment thereof binds specifically and with high affinity to both glycosylated and non-glycosylated human IL13, does-not bind mouse IL13, and neutralizes human IL activity at an approximate molar ratio of 1:2 (MAb:IL13). 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 4, naznačen time što se navedeno anti-ljudsko IL13 antitijelo ili njegov fragment vezan za antigen veže specifično i s visokim afinitetom na glikoziliranu i ne-glikoziliranu ljudsku IL13, ne veže mišju IL13 i neutralizira ljudsku IL13 aktivnost pri približnom molarnom omjeru 1: 2 (MAb: IL13).
Further advantages are that it is possible to emboss a surface relief directly onto the surface and that it is easier to print on metal surfaces. 
Daljnje prednosti su u tome što je moguće gravirati plošni reljef direktno na površini i što je lakše štampati na metalnim površinama.
A medicament comprising (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate potassium salt, in combination with a calcium antagonist for the prophylaxis or treatment of diseases in which insulin resistance is involved. 
2' (5-okso-4,5-dihidro-1,2,4metil)-1H-benzimidazol-7-karboksilat kalijevu sol za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija. . Lijek, naznačen time, da 2' (5-0kso-4,5-dihidro-1,2,4- profilaksu ili liječenje 2' (5-okso-4,5-dihidro-1,2,4metil) -1H-benzimidazol-7-karboksilat kalijevu sol, u kombinaciji s antagonistom kalcija za profilaksu ili liječenje oboljenja u kojima je sadržana inzulinska rezistencija.
In another embodiment the method further comprises administering an additional agent prior to, after, or simultaneously with the compound of formula (I) or a therapeutically acceptable salt thereof. 
Spoj ili terapijski prihvatljiva sol za primjenu prema patentnom zahtjevu 2 koja dalje sadrži administriranje dodatnog agensa prije, nakon, ili simultano sa spojem iz patentnog zahtjeva I ili njegovom terapijski prihvatljivom soli.
The pharmaceutical composition according to claim 1, wherein the neuraminidase inhibitor is oseltamivir or zanamivir. 
Farmaceutski pripravak u skladu sa zahtjevom 1 ili 2, naznačen time, da je neuraminidaza inhibitor oseltamivir ili zanamivir.
is —C2-6alkylene-NR3R4, —C2-6alkylene-guanidine or —C2-6alkylene-COOH wherein each of R3 and R4 independently is H, C1-4alkyl, Ω-hydroxy-C2-4alkylene or acyl or R3 and R4 form together with the nitrogen atom to which they are attached a heterocyclic group which may comprise a further heteroatom, and 
R; i Ray nezavisno H, C,ualkil, o-hidroksi-C,.galkilen ili acil ili Rz 1 R; skupa s atomom dušika na kojeg su vezani čine heterocikličku skupinu koja može sadržavati daljnji heteroatom, te R, je Z,-CH>-R:, -CH,-CO-0-CH>-Rs5
The compound according to claim 5 wherein R2 is H, OH, methyl, ethyl, methoxy, ethoxy, allyl or Bn. 
Tvar u skladu s patentnim zahtjevom 5 pri čemu je R2 OH, metil, etil, metoksi, etoksi, alil ili Bn.
In direct tabletting with preceding exposure to heat, the material to be pressed is heated immediately prior to tabletting at least to the softening temperature of component (C) and then pressed. 
Kod izravnog tabletiranja uz prethodno djelovanje topline se šarža koju treba sprešati zagrijava neposredno prije tabletiranja barem do temperature omekšavanja komponente (C), a zatim se spreša pomoću alata za tabletiranje.
Reference 9 in particular purports to disclose the manufacturing process for PROLEUKINTM, including details of expression, recovery, purification, formulation and finishing, but this disclosure is incomplete in several respects. 
Sastav se liofilizira, Referenca 9 osobito otkriva proces proizvodnje za PROLEUKINTY", uključujući detalje ekspresije, regeneracije, pročišćavanja, formuliranja i dovršavanja, ali ovo je otkriće nepotpuno u nekoliko aspekata.
The method for recovering heat according to claim 1, in which part of the low pressure steam obtained from stage 1 is used to generate electricity. 
Postupak povrata topline u skladu sa zahtjevom 1 naznačen time da se dio niskotlačne pare koja izlazi iz koraka 1 koristi za generiranje struje.
The piece of fitness equipment according to claim 1, wherein each of the first and second pressure chambers has an approximately circular cross-section. 
Fitnes uređaj prema zahtjevu 1, naznačen time da tlačna komora (20a) ima približno kružni poprečni presjek, pri čemu je tlačna komora (20a) poželjno izrađena od silikona.
The mixture was reacted in a Paar apparatus under 50 psi of hydrogen gas for 2h. 
Smjesa reagira u Paarovoj aparaturi pod tlakom vodika od 50 psi tijekom 2 h.
Intravenously, the most preferred doses will range from about 0.1 to about 10 mg/kg/minute during a constant rate infusion. 
Intravenozno, najpoželjnije doze su u opsegu od oko 0.1 do oko 10 mg/ke/minuti tijekom konstantne infuzije.
is a bicyclic ring system selected from the group consisting of tetrahydroisoquinolinyl, tetrahydroquinolinyl, indolyl, dihydroindolyl, indazolyl, dihydroindazolyl, and pyrrolopyridinyl; 
je biciklički sustav prstena, kojeg se bira iz skupine koju čine tetrahidroizokinolinil, tetrahidrokinolinil, indolil, dihidroindolil, indazolil, dihidroindazolil, te pirolopiridinil;
but also that the absorption of the stable thyroid hormone powder is improved, the dose being very accurately administrated and absorbed avoiding over/under-dosing. 
), već također da je poboljšana apsorpcija praha stabilnog tiroidnog hormona, doza je vrlo točno primijenjena 1 apsorbirana čime je izbjegnuto pre-/pod-doziranje.
is hydrogen, 2,2-dimethyl-propionyloxymethyl, or benzyl, wherein benzyl is optionally substituted with one to two fluorine atoms, —C1-C3 alkyl optionally substituted with 1 to 3 fluorine atoms, or —C1-C3 alkoxy; 
R? je vodik, 2,2-dimetilpropioniloksimetil ili benzil, gdje je benzil izborno supstituiran s jednim do dva atoma fluora, -C1-C3 alkilom, izborno supstituiranim s 1 do 3 atoma fluora, ili -Ci-C3 alkoksi;
The uracil compound or the salt thereof according to claim 1, wherein n represents 1 or 3; 
Spoj uracila ili njegove soli u skladu s patentnim zahtjevom 1, naznačen time, da n predstavlja 1 ili 3;
The reason for this is, as stated, that such packaging must be able to integrate different materials, i.e. metal and e.g. plastic. 
Razlog za to, kao što je navedeno, je taj što takvo pakiranje mora imati mogućnost da se uključe različiti materijali, na primjer, metal i, na primjer, plastika.
For such semi-permanent multi dose inhalers with disposable drug containers, the requirements to prevent drug accumulation are even stricter. 
Za takve poluzamjenjive imnhalatore sa zamjenjivim spremnicima za lijek zahtjevi za sprječavanje nakupljanja lijeka još su stroži.
The process according to claim 1, wherein the step of mixing the marine oil or the mixture of the polar fraction and the marine oil with the polar solvent is performed at a temperature of about 5° C. to about 40° C. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 9, pri čemu se korak miješanja ribljeg ulja ili smjese polarne frakcije i ribljeg ulja s polarnim otapalom provodi kod temperature od 5*C do 40*C.
A prosthetic heart valve comprising: a collapsible and expandable annular frame that is configured to be collapsed to a radially collapsed state for mounting on a delivery apparatus and expanded to a radially expanded state inside the body, the frame having an inflow end, an outflow end, and a longitudinal axis extending from the inflow end to the outflow end, the frame comprising a plurality of struts defining a plurality of cells; and 
Protetski zalistak na bazi katetera (100) konfiguriran da bude prešan do radijalno sklopljenog stanja na balonu uređaja za isporuku koji sadrži: sklopivi i proširivi prstenasti okvir (102), konfiguriran da se sklopi u radijalno sklopljeno stanje za montiranje na aparat za dostavljanje i proširen do radijalno proširenog stanja unutar tijela;
In one embodiment, a flowable composition is provided including: (a) a biodegradable thermoplastic polymer that is at least substantially insoluble in body fluid; (b) a biocompatible end-capped oligomeric liquid; and (c) a bioactive agent, a metabolite, or a prodrug thereof. The biocompatible end-capped oligomeric liquid is of the formula I, II, III, IV, or V: 
Tekući pripravak koji sadrži: biorazgradivi termoplastični poliesterski polimer koji je barem uglavnom netopiv u tjelesnoj tekućini; biokompatibilnu zaklopljenu oligomernu tekućinu; te biološki aktivno sredstvo, metabolit, ili njegov predlijek, pri čemu biokompatibilna zaklopljena oligomerna tekućina ima formulu I, II, III, IV, ili V: Rej Ra
The method of claim 68, wherein the human has hypercholesterolemia. The method of claim 67, wherein the double stranded RNAi agent is administered at a dose of about 0.01 mg/kg to about 10 mg/kg or about 0.5 mg/kg to about 50 mg/kg. 
(c) dvolančano RNAi sredstvo se treba primjenjivati u dozi od oko 0.01 mg/kg do oko 10 mg/kg, oko 0.5 mg/kg do oko 50 mg/kg, ili oko 10 mg/kg do oko 30 mg/kg; i/ili
feeding a slurry of such expandable thermoplastic microspheres in a liquid medium into a heating zone; 
(a) dodavanju mulja od takvih rastezljivih termoplastičnih mikrosfera u tekućem mediju u zonu grijanja;
Use of a mouse according to any one of claims 1 to 7 to produce a cell that expresses a human bispecific antibody. Use according to claim 19, where the cell comprises: a human VL nucleotide sequence encoding a human VL domain derived from a human Vk1-39Jk5 or a human Vk3-20Jk1 gene segment, wherein the human VL nucleotide sequence is fused, directly or through a linker, to a human immunoglobulin light chain constant sequence; 
(a) genski odsječak varijabilne regije lakog lanca humanog imunoglobulina koji kodira varijabilnu domenu lakog lanca humanog imunoglobulina izvedenu iz humanog segmenta gena VK1-39JK, pri čemu je genski odsječak varijabilne regije lakog lanca humanog imunoglobulina spojen izravno ili preko povezivača, na genski odsječak nepromjenjive regije lakog lanca humanog imunoglobulina, čime se dobiva gen koji kodira laki lanac humanog imunoglobulina;
From the above, it is clear that the valve 18 serves as an evacuation valve for the steam-producing thermoblock 10. 
Odozgo se jasno vidi da ventil 18 služi kao ventil za pražnjenje termobloka za dobivanje vodene pare 10.
The pure compactin is then fermented into pravastatin and isolated according to the methods disclosed in U.S. Patent No. 6,444,452 . 
Čisti se kompaktin zatim fermentira u pravastatin koji se izolira prema postupcima opisanim u U.S. Patentu 6,444,452.
imidazol-2-yl), or unsubstituted triazolyl (e.g.triazol-3-yl) or R9 represents an optionally substituted saturated 5 membered monocyclic heterocyclyl, for example 2-pyrrolidinonyl (e.g. 
Imidazol-2-il), ili nesupstituirani triazolil (npr.triazol-3-il) ili R9 predstavlja supstitut po izboru zasićenog 5-članog monocikličkog heterociklil, na primjer 2-pirolidinonil (npr.
Six formulations ET-NF A, ET-NF B, ET-NF C, ET-NF D, ET-NF E and ET-NF F were manufactured and used for further study of stability at different temperatures. 
Å est Oblika ET-NF A, ET-NF B, ET-NF C, ET-NF D, ET-NEF E i ET-NF F je proizvedeno i uporabljeno za dodatno ispitivanje stabilnosti na različitim temperaturama.
The VEGF antagonist and the alpha5beta1 antagonist can be administered in concurrent or sequential treatment cycles. 
HR P20150884 T1 antagonista anti-alfaSbetal, pri čemu se protutijelo antagonista anti- VEGF i protutijelo antagonista anti-alfa5beta1 primjenjuju u sukladnim ciklusima liječenja.
Whichever the localization of the pathogen, recurrent candidiasis is a difficult problem to manage. 
Gdje god da je lokalizacija patogena, recesivna kandidijaza je teško savladiv problem.
represents a triazolyl group, a pyridyl group or a pyrimidinyl group; 
predstavlja triazolil skupinu, piridil skupinu ili pirimidinil skupinu;
Apparatus according to claim 4, wherein the decoder (250) is further configured to recognize, based on an information in the data stream, and independent from a number of positions of the insignificant transform coefficients indicated by the previously extracted and associated first-type syntax elements, as to whether at a position with which a currently extracted first-type syntax element is associated, which indicates that at this position a significant transform coefficient is situated, a last significant transform coefficient in the transform coefficient block is situated. 
Uređaj prema zahtjevu 4, naznačen time, da je dokoder (250) nadalje konfiguriran tako, da na osnovi informacija u protoku podataka, i u ovisnosti od broja pozicija nesignifikantnih koeficijenata transformacije koji su prikazani putem prethodno izvučenih i pridruženih elemenata sintakse prvog tipa, raspoznaje da li je na toj poziciji s kojom je povezan jedan aktualni izvučeni element sintakse prvog tipa, što pokazuje da je na toj poziciji smješten signifikantni koeficijent transformacije, smješten posljednji signifikantmi koeficijent transformacije u bloku koeficijenata transformacije.
The crystallized pellets were mat and white. 
Kristaliziranc polete su neprozirnc i bijele.
The composition in accordance to the present invention may be prepared according to typical procedures normally employed in the formulation field for liquid preparations, like solutions, nail varnish, lotion or foam, or for semi-solid preparations, like cream or gel. 
Pripravak korišten u ovom izumu može se pripremiti prema tipičnim postupcima koji se normalno koriste u polju formuliranja tekućih preparata, poput otopina, laka za nokte, losiona ili pjene, ili polukrutih preparata, poput kreme ili gela.
28 and 28A), which can be fixed to the wrist 90 of a patient (FIG. 
- - narukvice (80), koja naročito može biti pričvršćena na ruku pacijenta (21) na zglobu (90);
An object of the present invention is to provide a device for recycling a mixture of polymethylmethacrylate (PMMA) and/or acrylonitrile-butadiene-styrene (ABS) and crosslinked polymethylmethacrylate (PMMA) which represents an improvement over the known art, by being economical in terms of operating costs and by enabling a recycling process to be achieved in a single passage. 
Jedan cilj predmetnog izuma je taj, da se osigura uređaj za recikliranje mješavine polimetilmetakrilata (PMMA) i/ili akrilonitril-butadien-stirena (ABS) i umreženog polimetilmetakrilata (PMMA) koji uređaj predstavlja poboljšanje u poznatoj struci, time što je ekonomičan s obzirom na troškove pogona i što omogućava da se dobije postupak recikliranja u samo jednom prolazu.
and R4 in combination with the nitrogen to which they are attached form a cyclic moiety selected from morpholino, pyrrolidinyl or piperazinyl. 
i R4 u kombinaciji s dušikom na koji su vezani tvore cikličku skupinu odabranu od morfolino, pirolidinila ili piperazinila.
Of course, it is necessary to take measures to protect the cells immediately after the sample has been taken. 
Naravno da je potrebno poduzeti mjere da se stanice zaštite neposredno nakon što je uzorak bio uzet.
An anti-CD40 antibody comprising a heavy chain comprising the amino acid sequence of SEQ ID NO: 41, and a light chain comprising the amino acid sequence of SEQ ID NO: 40. 
Protutijelo protiv CD40, naznačeno time što sadrži teški lanac, koji ima aminokiselinski slijed kao što je iznijet u SEQ ID NO: 41, te laki lanac, koji ima aminokiselinski slijed kao što je iznijet u SEQ ID NO: 40.
Pharmaceutical composition containing a nucleic acid according to any one of claims 1 to 12, a pharmaceutically acceptable carrier and, optionally, further auxiliary substances, additives and/or adjuvants. 
RNA molekule prema zahtjevu 1 naznačene time da se koriste kao medikament. Farmaceutski pripravak naznačen time da sadrži RNA molekulu prema zahtjevu 1, farmaceutski prihvatljiv nosač, te po izboru, dodatne pomoćne tvari, dodatke i/ili pomoćna sredstva.
The antibody or antigen binding portion thereof, of any one of the preceding claims, wherein the antibody is a human antibody, a humanized antibody or a chimeric antibody. 
Antitijelo ili njegov dio koji se veže za antigen, prema bilo kojem od prethodnih patentnih zahtjeva, naznačeno time što je antitijelo - humano antitijelo, humanizirano antitijelo ili himerno antitijelo.
o is an integer ranging 0 to 4; 
o je cijeli broj u rasponu 0 do 4;
The gown according to claim 3 wherein the first cord and the second cord are temporarily attached at the top portion of the gown using hook and loop devices for the temporary secured attachment located in the shoulder area of the left and right side portions of the back portion of the gown. 
Kuta prema zahtjevu 2, naznačena time, da svaka vrpca privremeno pričvršćena na oba mjesta na gornjem dijelu kute uz primjenu principa kopče i karike za privremeno pričvršćivanje, i koje se nalaze u području ramena lijevog i desnog postranog dijela (3, 4) stražnjeg dijela kute.
represents a hydrogen atom, a fluoro atom or a chloro atom, or a methyl, methoxy, difluoromethyl or trifluoromethyl group; 
R? predstavlja vodikov atom, fluorov atom ili klorov atom, ili skupinu metil, metoksi, difluormetil ili trifluormetil;
A method for producing 2n pollen, wherein said method comprises cultivating a plant obtained by a method of any of claims 1 to 3. 
dobivanje biljke koja proizvodi pelud 2n, metodom iz bilo kojeg od zahtjeva 1 do 3; uzgoj te biljke;
a barrel (21) with a cartridge chambering end and a firing end; 
spremnik (21) s krajem za komoru naboja i krajem za paljbu;
A particularly beneficial use of the invention, is in realizing a method of increasing the plant capacity of the melamine production zone of a pre-existing facility for the integrated production of urea and melamine. 
HR P20190746 T1 tekućine/plina u sklopu pogona za proizvodnju uree i ispušnih plinova melamina putem kombinirane kondenzacije u neizravnoj izmjeni topline s vodenim mlazom uree.
The compound according to claim 2, wherein the compound is represented by Formula Ia: or a pharmaceutically acceptable salt, or stereoisomer thereof; wherein is selected from C1-4alkoxy, di-C1-4alkylamino, C3-6cycloalkyl, C4 -6heterocycloalkyl,and C5-6heteroaryl, wherein the C3-6cycloalkyl, C4-6heterocycloalkyl, or C5-6heteroaryl of R1 is unsubstituted or substituted by 1 to 2 substituents independently selected from halo, C1-4alkyl, C1-4alkoxy, diC1-4alkylamino, and hydroxycarbonyl; 
Spoj prema zahtjevu 2, naznačen time, da je spoj predstavljen s Formulom Ia: ila) ili njegova farmaceutski prihvatljiva sol, ili njegov stereoizomer; pri čemu R' je odabran iz niza koji čine C,ualkoksi, di-Crgalkilamino, Csgcikloalkil, Cygheterocikloalkil, i Cs. sheteroaril, gdje je Ca.gcikloalkil, Ca gheterocikloalkil, ili Cs sheteroaril od R', nesupstituiran ili supstituiran s 1 do 2 supstituenta neovisno odabrana iz niza koji čine halo, Craalkil, Crgalkoksi, diC,galkilamino, i hidroksikarbonil;
5-HT2C Receptor Efficacy as Determined by Fluorometry. 
Djelotvornost 5-HT2c receptora određena fluorometrijom
A compound for use of Claim 10 wherein the pulmonary disorder is chronic obstructive pulmonary disease or asthma. 
Spoj u skladu s patentnim zahtjevom 8, naznačen time, da je plućna bolest kronična opstruktivna bolest pluća ili astma.
is alkyl, aminoalkyl, or alkanol; each X13 is independently hydrogen, hydroxy, alicyclic, amino, aminoalkyl halogen, alkyl, heteroaryl, boronic acid or aryl; 
X, je alkil, aminoalkil ili alkanol; svaki X;3s je nezavisno vodik, hidroksi, alicikličan, amino, aminoalkil, halogen, alkil, heteroaril, boronska kiselina ili aril; z je broj koji nije negativan; 1 amin koji odgovara Formuli 2b sadrži najmanje jednu alilnu skupinu.
the asparagine at position 11 of the BC loop (SEQ ID NO: 34) is substituted with an amino acid selected from the group consisting of A, C, F, H, P, Q, R, S, and Y. 
asparagin na položaju 11 u petlji BC (SEQ ID NO: 34) je zamijenjen aminokiselinom koju se bira iz skupine koju čine A, C, F, H, P, Q, R, S i Y.
The pharmaceutical combination according to claim 2 for use in the therapy of colorectal cancer wherein the combination contains regorafenib in an amount of 10 to 100 mg and acetylsalicylic acid in an amount of 70 to 350 mg 
Farmaceutska kombinacija prema zahtjevu 2 za uporabu za terapiju raka debelog crijeva naznačena time što kombinacija sadrži regorafenib u količini od 10 do 100 mg i acetilsalicilnu kiselinu u količini od 70 do 350 mg